Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel GPR119 receptor agonists disclosed by Bristol-Myers Squibb

Dec. 7, 2011

Kowa identifies new cholesterol ester transfer protein inhibitors

Dec. 7, 2011

Amicus initiates phase II study of investigational chaperone with ERT in Pompe's disease

Dec. 5, 2011

Results of phase II evaluation of evacetrapib presented

Dec. 5, 2011

Generex provides update on clinical and regulatory status of buccal insulin spray

Dec. 2, 2011

Evotec patents novel orexin OX2 receptor antagonists

Dec. 2, 2011

Omthera Pharmaceuticals completes enrollment in EVOLVE study

Dec. 1, 2011

Advinus Therapeutics completes proof-of-concept study of GKM-001

Dec. 1, 2011

Novel orexin receptor antagonists emerge from R&D at Evotec

Dec. 1, 2011

GlaxoSmithKline presents new AMPK activators

Dec. 1, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...